Majority of researchers supporting GlaxoSmithKline's Avandia 'had ties to the firm;' Takeda pulls SR-Competact MAA
The majority of researchers who have published articles supporting UK drug giant GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) after it was linked to heart disease in 2007 had financial ties to the company, according to a Mayo Clinic report reported in the British Medical Journal.
A US Senate committee more recently alleged that GSK knew that Avandia, which generated sales of nearly $1.2 billion last year, posed increased risk of heart attacks, a conclusion which has been rejected by the company, and also criticized the nation's drug regulatory body, the Food and Drug Administration, for failings (The Pharma Letter February 22).
The Mayo researchers examined more than 200 articles that appeared after an analysis in the New England Journal of Medicine linked Avandia to a 43% increased risk of heart attacks, and a subsequent clinical trial found no greater danger of heart disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze